Drake L A, Millikan L E
Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Arch Dermatol. 1995 Dec;131(12):1403-8.
Eczematous dermatitis is commonly characterized by intense pruritus. Current treatment modalities for this condition, regardless of its cause, are primarily directed at blunting the cutaneous inflammatory response and thereby providing relief of pruritus. To expand on our previous findings in atopic dermatitis, the present multicenter double-blind trial was conducted to evaluate the safety and antipruritic efficacy of 5% doxepin hydrochloride cream in patients with lichen simplex chronicus (n = 136), nummular eczema (n = 87), or contact dermatitis (n = 86). A total of 309 patients with moderate to severe pruritus were randomly assigned to apply either doxepin cream (n = 154) or vehicle cream (n = 155) to eczematous areas four times per day for a period of 7 days. Efficacy was assessed using a pruritus severity rating scale, a Physician's Global Evaluation for pruritus relief, and a Visual Analogue Scale for pruritus relief.
Twenty-four hours after initiation of treatment, and continuing throughout the remainder of the study, patients treated with doxepin cream experienced significantly greater pruritus relief than did vehicle-treated patients as determined by all efficacy parameters (P < .002). Sixty percent of doxepin-treated patients experienced pruritus relief within 24 hours. The response rate increased to 84% by conclusion of the study. As judged by significant changes (P < or = .05) occurring in at least one assessment of efficacy, doxepin cream provided pruritus relief in all forms of eczematous dermatitis that were examined. The study medication was well tolerated. The two most common adverse effects, stinging at the site of application and drowsiness, were usually transient and mild to moderate in severity.
Topical application of doxepin provides significant antipruritic activity with a favorable safety profile, suggesting a role for doxepin cream in the symptomatic treatment of pruritus associated with eczematous dermatitis.
湿疹性皮炎通常以剧烈瘙痒为特征。目前针对这种病症的治疗方法,无论其病因如何,主要是针对减轻皮肤炎症反应,从而缓解瘙痒。为了进一步拓展我们之前在特应性皮炎方面的研究结果,开展了本次多中心双盲试验,以评估5%盐酸多塞平乳膏对慢性单纯性苔藓患者(n = 136)、钱币状湿疹患者(n = 87)或接触性皮炎患者(n = 86)的安全性和止痒疗效。总共309例中重度瘙痒患者被随机分配,每天4次在湿疹部位涂抹多塞平乳膏(n = 154)或赋形剂乳膏(n = 155),持续7天。使用瘙痒严重程度评分量表、医生对瘙痒缓解的整体评估以及瘙痒缓解视觉模拟量表来评估疗效。
治疗开始24小时后,并且在研究的其余时间内持续观察发现,通过所有疗效参数判定,使用多塞平乳膏治疗的患者比使用赋形剂治疗的患者瘙痒缓解程度明显更大(P <.002)。60%接受多塞平治疗的患者在24小时内瘙痒得到缓解。到研究结束时,缓解率增至84%。根据至少一项疗效评估中出现的显著变化(P ≤.05)判断,多塞平乳膏对所有检查的湿疹性皮炎形式均能缓解瘙痒。研究药物耐受性良好。两种最常见的不良反应,即用药部位刺痛和嗜睡,通常是短暂的,严重程度为轻至中度。
局部应用多塞平具有显著的止痒活性且安全性良好,这表明多塞平乳膏在与湿疹性皮炎相关的瘙痒症状治疗中具有一定作用。